Since the report of third quarter results, Cingulate, Inc. (NASDAQ:CING) has executed a $5 million capital raise, completed its fast-fed study and reported safety results from its Phase III trials.

Several research analysts have recently issued reports on CING shares. Roth Mkm initiated coverage on shares of Cingulate in a research note on Friday, January 10th. They issued a “buy” rating ...